Interaction of major genes predisposing to hepatocellular carcinoma with genes encoding signal transduction pathways influences tumor phenotype and prognosis

World Journal of Gastroenterology

Volumn 14, Issue 43, 2008, Pages 6601-6615

  Feo, Francesco ^a   Frau, Maddalena ^a   Pascale, Rosa Maria ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

Apoptosis; Cell cycle; Cell proliferation; Genetic predisposition; Hepatocarcinogenesis; Polygenic disease; Proteasomal degradation; Redifferentiation; Signal transduction pathways

Indexed keywords

CELL CYCLE PROTEIN 37; EXPORTIN 1; HEAT SHOCK PROTEIN 90; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; RAS PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXM1; UNCLASSIFIED DRUG;

APOPTOSIS; CELL CYCLE REGULATION; EDITORIAL; ENZYME DEGRADATION; GENE FUNCTION; GENE INTERACTION; GENE LOCUS; GENE MAPPING; GENE TARGETING; GENETIC PREDISPOSITION; GENETIC RESISTANCE; GENOMIC INSTABILITY; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; PHENOTYPE; PROGNOSIS; RISK FACTOR; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION; UPREGULATION;

EID: 63449112698     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.6601     Document Type: Editorial

References (144)

1. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004; 5: 215-219
2. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-346
3. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-687
4. Tanaka Y, Hanada K, Mizokami M, Yeo AE, Shih JW, Gojobori T, Alter HJ. Inaugural Article: A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA 2002; 99: 15584-15589
5. Indulski JA, Lutz W. Metabolic genotype in relation to individual susceptibility to environmental carcinogens. Int Arch Occup Environ Health 2000; 73: 71-85
6. Kato S, Tajiri T, Matsukura N, Matsuda N, Taniai N, Mamada H, Yoshida H, Kiyam T, Naito Z. Genetic polymorphisms of aldehyde dehydrogenase 2, cytochrome p450 2E1 for liver cancer risk in HCV antibody-positive japanese patients and the variations of CYP2E1 mRNA expression levels in the liver due to its polymorphism. Scand J Gastroenterol 2003; 38: 886-893
7. Agundez JA, Olivera M, Ladero JM, Rodriguez-Lescure A, Ledesma MC, Diaz-Rubio M, Meyer UA, Benitez J. Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics 1996; 6: 501-512
8. Hsieh LL, Huang RC, Yu MW, Chen CJ, Liaw YF. L-myc, GST M1 genetic polymorphism and hepatocellular carcinoma risk among chronic hepatitis B carriers. Cancer Lett 1996; 103: 171-176
9. Taylor JA, Bell DA, Nagorney D. L-myc proto-oncogene alleles and susceptibility to hepatocellular carcinoma. Int J Cancer 1993; 54: 927-930
10. Sonzogni L, Silvestri L, De Silvestri A, Gritti C, Foti L, Zavaglia C, Bottelli R, Mondelli MU, Civardi E, Silini EM. Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease. Hepatology 2002; 36: 195-201
11. Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, Chen PJ, Hsiao TJ, Lee PH, Chen CJ. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000; 92: 1159-1164
12. Cai RL, Meng W, Lu HY, Lin WY, Jiang F, Shen FM. Segregation analysis of hepatocellular carcinoma in a moderately high-incidence area of East China. World J Gastroenterol 2003; 9: 2428-2432
13. Fernandez E, La Vecchia C, D'Avanzo B, Negri E, Franceschi S. Family history and the risk of liver, gallbladder, and pancreatic cancer. Cancer Epidemiol Biomarkers Prev 1994; 3: 209-212
14. Hemminki K, Li X. Familial risks of cancer as a guide to gene identification and mode of inheritance. Int J Cancer 2004; 110: 291-294
15. Feo F, Pascale RM, Simile MM, De Miglio MR, Muroni MR, Calvisi D. Genetic alterations in liver carcinogenesis: implications for new preventive and therapeutic strategies. Crit Rev Oncog 2000; 11: 19-62
16. Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK, Thorgeirsson SS. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 2004; 36: 1306-1311
17. Rebouissou S, Bioulac-Sage P, Zucman-Rossi J. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol 2008; 48: 163-170
18. Korstanje R, Paigen B. From QTL to gene: the harvest begins. Nat Genet 2002; 31: 235-236
19. Farber E, Sarma DS. Hepatocarcinogenesis: a dynamic cellular perspective. Lab Invest 1987; 56: 4-22
20. Garcea R, Daino L, Pascale R, Simile MM, Puddu M, Frassetto S, Cozzolino P, Seddaiu MA, Gaspa L, Feo F. Inhibition of promotion and persistent nodule growth by S-adenosyl-L-methionine in rat liver carcinogenesis: role of remodeling and apoptosis. Cancer Res 1989; 49: 1850-1856
21. Zhou XD. Recurrence and metastasis of hepatocellular carcinoma: progress and prospects. Hepatobiliary Pancreat Dis Int 2002; 1: 35-41
22. Dragani TA, Manenti G, Della Porta G. Genetic susceptibility to murine hepatocarcinogenesis is associated with high growth rate of NDEA-initiated hepatocytes. J Cancer Res Clin Oncol 1987; 113: 223-229
23. Manenti G, Binelli G, Gariboldi M, Canzian F, De Gregorio L, Falvella FS, Dragani TA, Pierotti MA. Multiple loci affect genetic predisposition to hepatocarcinogenesis in mice. Genomics 1994; 23: 118-124
24. Denda A, Kitayama W, Konishi Y, Yan Y, Fukamachi Y, Miura M, Gotoh S, Ikemura K, Abe T, Higashi T, Higashi K. Genetic properties for the suppression of development of putative preneoplastic glutathione S-transferase placental form-positive foci in the liver of carcinogen-resistant DRH strain rats. Cancer Lett 1999; 140: 59-67
25. Feo F, De Miglio MR, Simile MM, Muroni MR, Calvisi DF, Frau M, Pascale RM. Hepatocellular carcinoma as a complex polygenic disease. Interpretive analysis of recent developments on genetic predisposition. Biochim Biophys Acta 2006; 1765: 126-147
26. Pascale RM, Simile MM, DeMiglio MR, Muroni MR, Gaspa L, Dragani TA, Feo F. The BN rat strain carries dominant hepatocarcinogen resistance loci. Carcinogenesis 1996; 17: 1765-1768
27. Wood GA, Korkola JE, Lee VM, Sarma DS, Archer MC. Resistance of Copenhagen rats to chemical induction of glutathione S-transferase 7-7-positive liver foci. Carcinogenesis 1997; 18: 1745-1750
28. Wood GA, Sarma DS, Archer MC. Resistance to the promotion of glutathione S-transferase 7-7-positive liver lesions in Copenhagen rats. Carcinogenesis 1999; 20: 1169-1175
29. Enomoto K, Farber E. Kinetics of phenotypic maturation of remodeling of hyperplastic nodules during liver carcinogenesis. Cancer Res 1982; 42: 2330-2335
30. Wood GA, Sarma DS, Archer MC. Inheritance of resistance to promotion of preneoplastic liver lesions in Copenhagen rats. Exp Biol Med (Maywood) 2001; 226: 831-835
31. Calvisi DF, Pinna F, Pellegrino R, Sanna V, Sini M, Daino L, Simile MM, De Miglio MR, Frau M, Tomasi ML, Seddaiu MA, Muroni MR, Feo F, Pascale RM. Ras-driven proliferation and apoptosis signaling during rat liver carcinogenesis is under genetic control. Int J Cancer 2008; 123: 2057-2064
32. Liu H, Higashi K, Hiai H. Role of resistant Drh1 locus in chemical carcinogen-induced hepatocarcinogenesis in rats: analysis with a speed congenic strain. Cancer Sci 2005; 96: 164-169
33. Gariboldi M, Manenti G, Canzian F, Falvella FS, Pierotti MA, Della Porta G, Binelli G, Dragani TA. Chromosome mapping of murine susceptibility loci to liver carcinogenesis. Cancer Res 1993; 53: 209-211
34. Bilger A, Bennett LM, Carabeo RA, Chiaverotti TA, Dvorak C, Liss KM, Schadewald SA, Pitot HC, Drinkwater NR. A potent modifier of liver cancer risk on distal mouse chromosome 1: linkage analysis and characterization of congenic lines. Genetics 2004; 167: 859-866
35. Poole TM, Drinkwater NR. Two genes abrogate the inhibition of murine hepatocarcinogenesis by ovarian hormones. Proc Natl Acad Sci USA 1996; 93: 5848-5853
36. Lee GH, Bennett LM, Carabeo RA, Drinkwater NR. Identification of hepatocarcinogen-resistance genes in DBA/2 mice. Genetics 1995; 139: 387-395
37. Lee GH, Drinkwater NR. The Hcr (hepatocarcinogen resistance) loci of DBA/2J mice partially suppress phenotypic expression of the Hcs (hepatocarcinogen sensitivity) loci of C3H/HeJ mice. Carcinogenesis 1995; 16: 1993-1996
38. Dragani TA, Manenti G, Della Porta G. Quantitative analysis of genetic susceptibility to liver and lung carcinogenesis in mice. Cancer Res 1991; 51: 6299-6303
39. Manenti G, Galvan A, Falvella FS, Pascale RM, Spada E, Milani S, Gonzalez Neira A, Feo F, Dragani TA. Genetic control of resistance to hepatocarcinogenesis by the mouse Hpcr3 locus. Hepatology 2008; 48: 617-623
40. Melhem MF, Kunz HW, Gill TJ 3rd. A major histocompatibility complex-linked locus in the rat critically influences resistance to diethylnitrosamine carcinogenesis. Proc Natl Acad Sci USA 1993; 90: 1967-1971
41. Rao KN, Shinozuka H, Kunz HW, Gill TJ 3rd. Enhanced susceptibility to a chemical carcinogen in rats carrying MHC-linked genes influencing development (GRC). Int J Cancer 1984; 34: 113-120
42. De Miglio MR, Canzian F, Pascale RM, Simile MM, Muroni MR, Calvisi D, Romeo G, Feo F. Identification of genetic loci controlling hepatocarcinogenesis on rat chromosomes 7 and 10. Cancer Res 1999; 59: 4651-4657
43. De Miglio MR, Pascale RM, Simile MM, Muroni MR, Calvisi DF, Virdis P, Bosinco GM, Frau M, Seddaiu MA, Ladu S, Feo F. Chromosome mapping of multiple loci affecting the genetic predisposition to rat liver carcinogenesis. Cancer Res 2002; 62: 4459-4463
44. De Miglio MR, Pascale RM, Simile MM, Muroni MR, Virdis P, Kwong KM, Wong LK, Bosinco GM, Pulina FR, Calvisi DF, Frau M, Wood GA, Archer MC, Feo F. Polygenic control of hepatocarcinogenesis in Copenhagen x F344 rats. Int J Cancer 2004; 111: 9-16
45. Zeng ZZ, Higashi S, Kitayama W, Denda A, Yan Y, Matsuo K, Konishi Y, Hiai H, Higashi K. Genetic resistance to chemical carcinogen-induced preneoplastic hepatic lesions in DRH strain rats. Cancer Res 2000; 60: 2876-2881
46. Yan Y, Zeng ZZ, Higashi S, Denda A, Konishi Y, Onishi S, Ueno H, Higashi K, Hiai H. Resistance of DRH strain rats to chemical carcinogenesis of liver: genetic analysis of later progression stage. Carcinogenesis 2002; 23: 189-196
47. Fujiwara Y, Monden M, Mori T, Nakamura Y, Emi M. Frequent multiplication of the long arm of chromosome 8 in hepatocellular carcinoma. Cancer Res 1993; 53: 857-860
48. Wong N, Lai P, Lee SW, Fan S, Pang E, Liew CT, Sheng Z, Lau JW, Johnson PJ. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis. Am J Pathol 1999; 154: 37-43
49. Okamoto H, Yasui K, Zhao C, Arii S, Inazawa J. PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas. Hepatology 2003; 38: 1242-1249
50. Ogawa K, Osanai M, Obata M, Ishizaki K, Kamiya K. Gain of chromosomes 15 and 19 is frequent in both mouse hepatocellular carcinoma cell lines and primary tumors, but loss of chromosomes 4 and 12 is detected only in the cell lines. Carcinogenesis 1999; 20: 2083-2088
51. De Miglio MR, Simile MM, Muroni MR, Calvisi DF, Virdis P, Asara G, Frau M, Bosinco GM, Seddaiu MA, Daino L, Feo F, Pascale RM. Phenotypic reversion of rat neoplastic liver nodules is under genetic control. Int J Cancer 2003; 105: 70-75
52. Chang WY. Complete spontaneous regression of cancer: four case reports, review of literature, and discussion of possible mechanisms involved. Hawaii Med J 2000; 59: 379-387
53. De Miglio MR, Virdis P, Calvisi DF, Frau M, Muroni MR, Simile MM, Daino L, Careddu GM, Sanna-Passino E, Pascale RM, Feo F. Mapping a sex hormone-sensitive gene determining female resistance to liver carcinogenesis in a congenic F344.BN-Hcs4 rat. Cancer Res 2006; 66: 10384-10390
54. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH, Felsher DW. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004; 431: 1112-1117
55. Simile MM, De Miglio MR, Muroni MR, Frau M, Asara G, Serra S, Muntoni MD, Seddaiu MA, Daino L, Feo F, Pascale RM. Down-regulation of c-myc and Cyclin D1 genes by antisense oligodeoxy nucleotides inhibits the expression of E2F1 and in vitro growth of HepG2 and Morris 5123 liver cancer cells. Carcinogenesis 2004; 25: 333-341
56. Garcea R, Daino L, Pascale R, Simile MM, Puddu M, Ruggiu ME, Seddaiu MA, Satta G, Sequenza MJ, Feo F. Protooncogene methylation and expression in regenerating liver and preneoplastic liver nodules induced in the rat by diethylnitrosamine: effect of variations of S-adenosylmethionine:S-adenosylhomocysteine ratio. Carcinogenesis 1989; 10: 1183-1192
57. Pascale RM, Marras V, Simile MM, Daino L, Pinna G, Bennati S, Carta M, Seddaiu MA, Massarelli G, Feo F. Chemoprevention of rat liver carcinogenesis by S-adenosyl-L-methionine: a long-term study. Cancer Res 1992; 52: 4979-4986
58. Pascale RM, Simile MM, De Miglio MR, Muroni MR, Calvisi DF, Asara G, Casabona D, Frau M, Seddaiu MA, Feo F. Cell cycle deregulation in liver lesions of rats with and without genetic predisposition to hepatocarcinogenesis. Hepatology 2002; 35: 1341-1350
59. De Miglio MR, Simile MM, Muroni MR, Pusceddu S, Calvisi D, Carru A, Seddaiu MA, Daino L, Deiana L, Pascale RM, Feo F. Correlation of c-myc overexpression and amplification with progression of preneoplastic liver lesions to malignancy in the poorly susceptible Wistar rat strain. Mol Carcinog 1999; 25: 21-29
60. Pascale RM, Simile MM, Calvisi DF, Frau M, Muroni MR, Seddaiu MA, Daino L, Muntoni MD, De Miglio MR, Thorgeirsson SS, Feo F. Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer. Hepatology 2005; 42: 1310-1319
61. Hunter T, Poon RY. Cdc37: a protein kinase chaperone? Trends Cell Biol 1997; 7: 157-161
62. Stepanova L, Leng X, Parker SB, Harper JW. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev 1996; 10: 1491-1502
63. Dai K, Kobayashi R, Beach D. Physical interaction of mammalian CDC37 with CDK4. J Biol Chem 1996; 271: 22030-22034
64. Crosby ME, Almasan A. Opposing roles of E2Fs in cell proliferation and death. Cancer Biol Ther 2004; 3: 1208-1211
65. Ohtani N, Brennan P, Gaubatz S, Sanij E, Hertzog P, Wolvetang E, Ghysdael J, Rowe M, Hara E. Epstein-Barr virus LMP1 blocks p16INK4a-RB pathway by promoting nuclear export of E2F4/5. J Cell Biol 2003; 162: 173-183
66. Marshall CJ. Ras effectors. Curr Opin Cell Biol 1996; 8: 197-204
67. Feig LA, Buchsbaum RJ. Cell signaling: life or death decisions of ras proteins. Curr Biol 2002; 12: R259-R261
68. Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Oncogene 2003; 22: 8999-9006
69. Johnston AM, Naselli G, Gonez LJ, Martin RM, Harrison LC, DeAizpurua HJ. SPAK, a STE20/SPS1-related kinase that activates the p38 pathway. Oncogene 2000; 19: 4290-4297
70. Ura S, Masuyama N, Graves JD, Gotoh Y. MST1-JNK promotes apoptosis via caspase-dependent and independent pathways. Genes Cells 2001; 6: 519-530
71. Khokhlatchev A, Rabizadeh S, Xavier R, Nedwidek M, Chen T, Zhang XF, Seed B, Avruch J. Identification of a novel Ras-regulated proapoptotic pathway. Curr Biol 2002; 12: 253-265
72. + pump 4b and the proapoptotic tumor suppressor Ras-associated factor 1 (RASSF1). J Biol Chem 2004; 279: 31318-31328
73. Guicciardi ME, Gores GJ. AIP1: a new player in TNF signaling. J Clin Invest 2003; 111: 1813-1815
74. Xu XX, Yi T, Tang B, Lambeth JD. Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2. Oncogene 1998; 16: 1561-1569
75. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F, Katsanakis KD, Rose DW, Mischak H, Sedivy JM, Kolch W. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 1999; 401: 173-177
76. Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta 2002; 1555: 14-20
77. Lin YW, Yang JL. Cooperation of ERK and SCFSkp2 for MKP-1 destruction provides a positive feedback regulation of proliferating signaling. J Biol Chem 2006; 281: 915-926
78. Wong J, Zhang J, Si X, Gao G, Luo H. Inhibition of the extracellular signal-regulated kinase signaling pathway is correlated with proteasome inhibitor suppression of coxsackievirus replication. Biochem Biophys Res Commun 2007; 358: 903-907
79. De Miglio MR, Muroni MR, Simile MM, Virdis P, Asara G, Frau M, Calvisi DF, Seddaiu MA, Pascale RM, Feo F. Frequent loss of heterozygosity at the Hcr1 (hepatocarcinogenesis resistance) locus on chromosome 10 in primary hepatocellular carcinomas from LFF1 rat strain. Hepatology 2001; 33: 1110-1117
80. Wang HY, Cheng Z, Malbon CC. Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett 2003; 191: 229-237
81. Bang YJ, Kwon JH, Kang SH, Kim JW, Yang YC. Increased MAPK activity and MKP-1 overexpression in human gastric adenocarcinoma. Biochem Biophys Res Commun 1998; 250: 43-47
82. Vicent S, Garayoa M, Lopez-Picazo JM, Lozano MD, Toledo G, Thunnissen FB, Manzano RG, Montuenga LM. Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Clin Cancer Res 2004; 10: 3639-3649
83. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999; 18: 813-822
84. Grammer TC, Blenis J. Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases. Oncogene 1997; 14: 1635-1642
85. Barry OP, Mullan B, Sheehan D, Kazanietz MG, Shanahan F, Collins JK, O'Sullivan GC. Constitutive ERK1/2 activation in esophagogastric rib bone marrow micrometastatic cells is MEK-independent. J Biol Chem 2001; 276: 15537-15546
86. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 2008; 8: 438-449
87. Major ML, Lepe R, Costa RH. Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylation-dependent recruitment of p300/CBP coactivators. Mol Cell Biol 2004; 24: 2649-2661
88. Wang IC, Chen YJ, Hughes D, Petrovic V, Major ML, Park HJ, Tan Y, Ackerson T, Costa RH. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol 2005; 25: 10875-10894
89. Rauhala HE, Porkka KP, Tolonen TT, Martikainen PM, Tammela TL, Visakorpi T. Dual-specificity phosphatase 1 and serum/ glucocorticoid-regulated kinase are downregulated in prostate cancer. Int J Cancer 2005; 117: 738-745
90. Shimada K, Nakamura M, Ishida E, Higuchi T, Tanaka M, Ota I, Konishi N. c-Jun NH2 terminal kinase activation and decreased expression of mitogen-activated protein kinase phosphatase-1 play important roles in invasion and angiogenesis of urothelial carcinomas. Am J Pathol 2007; 171: 1003-1012
91. Tsujita E, Taketomi A, Gion T, Kuroda Y, Endo K, Watanabe A, Nakashima H, Aishima S, Kohnoe S, Maehara Y. Suppressed MKP-1 is an independent predictor of outcome in patients with hepatocellular carcinoma. Oncology 2005; 69: 342-347
92. Calvisi DF, Pinna F, Meloni F, Ladu S, Pellegrino R, Sini M, Daino L, Simile MM, De Miglio MR, Virdis P, Frau M, Tomasi ML, Seddaiu MA, Muroni MR, Feo F, Pascale RM. Dual-specificity phosphatase 1 ubiquitination in extracellular signal-regulated kinase-mediated control of growth in human hepatocellular carcinoma. Cancer Res 2008; 68: 4192-4200
93. Kim IM, Ackerson T, Ramakrishna S, Tretiakova M, Wang IC, Kalin TV, Major ML, Gusarova GA, Yoder HM, Costa RH, Kalinichenko VV. The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res 2006; 66: 2153-2161
94. Costa RH, Kalinichenko VV, Major ML, Raychaudhuri P. New and unexpected: forkhead meets ARF. Curr Opin Genet Dev 2005; 15: 42-48
95. Wierstra I, Alves J. FOXM1, a typical proliferation-associated transcription factor. Biol Chem 2007; 388: 1257-1274
96. Yoshida Y, Wang IC, Yoder HM, Davidson NO, Costa RH. The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer. Gastroenterology 2007; 132: 1420-1431
97. Wang Z, Banerjee S, Kong D, Li Y, Sarkar FH. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res 2007; 67: 8293-8300
98. Zhao YY, Gao XP, Zhao YD, Mirza MK, Frey RS, Kalinichenko VV, Wang IC, Costa RH, Malik AB. Endothelial cell-restricted disruption of FoxM1 impairs endothelial repair following LPS-induced vascular injury. J Clin Invest 2006; 116: 2333-2343
99. Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, Morrison A, Clevers H, Medema RH. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005; 7: 126-136
100. Wang X, Kiyokawa H, Dennewitz MB, Costa RH. The Forkhead Box m1b transcription factor is essential for hepatocyte DNA replication and mitosis during mouse liver regeneration. Proc Natl Acad Sci USA 2002; 99: 16881-16886
101. Krupczak-Hollis K, Wang X, Dennewitz MB, Costa RH. Growth hormone stimulates proliferation of old-aged regenerating liver through forkhead box m1b. Hepatology 2003; 38: 1552-1562
102. Kalinichenko VV, Major ML, Wang X, Petrovic V, Kuechle J, Yoder HM, Dennewitz MB, Shin B, Datta A, Raychaudhuri P, Costa RH. Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev 2004; 18: 830-850
103. Bektas N, Haaf A, Veeck J, Wild PJ, Luscher-Firzlaff J, Hartmann A, Knuchel R, Dahl E. Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer 2008; 8: 42
104. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006; 38: 1043-1048
105. Katoh Y, Katoh M. Hedgehog signaling pathway and gastric cancer. Cancer Biol Ther 2005; 4: 1050-1054
106. Teh MT, Wong ST, Neill GW, Ghali LR, Philpott MP, Quinn AG. FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res 2002; 62: 4773-4780
107. Pasca di Magliano M, Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer 2003; 3: 903-911
108. Kasper M, Regl G, Frischauf AM, Aberger F. GLI transcription factors: mediators of oncogenic Hedgehog signalling. Eur J Cancer 2006; 42: 437-445
109. Crompton T, Outram SV, Hager-Theodorides AL. Sonic hedgehog signalling in T-cell development and activation. Nat Rev Immunol 2007; 7: 726-735
110. Kim Y, Yoon JW, Xiao X, Dean NM, Monia BP, Marcusson EG. Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells. Cancer Res 2007; 67: 3583-3593
111. Kise Y, Takenaka K, Tezuka T, Yamamoto T, Miki H. Fused kinase is stabilized by Cdc37/Hsp90 and enhances Gli protein levels. Biochem Biophys Res Commun 2006; 351: 78-84
112. Lasagna N, Fantappie O, Solazzo M, Morbidelli L, Marchetti S, Cipriani G, Ziche M, Mazzanti R. Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. Cancer Res 2006; 66: 2673-2682
113. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007; 121: 2373-2380
114. Ying L, Hofseth AB, Browning DD, Nagarkatti M, Nagarkatti PS, Hofseth LJ. Nitric oxide inactivates the retinoblastoma pathway in chronic inflammation. Cancer Res 2007; 67: 9286-9293
115. Zingarelli B, Hake PW, Yang Z, O'Connor M, Denenberg A, Wong HR. Absence of inducible nitric oxide synthase modulates early reperfusion-induced NF-kappaB and AP-1 activation and enhances myocardial damage. FASEB J 2002; 16: 327-342
116. Deora AA, Hajjar DP, Lander HM. Recruitment and activation of Raf-1 kinase by nitric oxide-activated Ras. Biochemistry 2000; 39: 9901-9908
117. Ellerhorst JA, Ekmekcioglu S, Johnson MK, Cooke CP, Johnson MM, Grimm EA. Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma. Oncogene 2006; 25: 3956-3962
118. Zhao Q, Lee FS. Mitogen-activated protein kinase/ERK kinase kinases 2 and 3 activate nuclear factor-kappaB through IkappaB kinase-alpha and IkappaB kinase-beta. J Biol Chem 1999; 274: 8355-8358
119. Simile MM, Pagnan G, Pastorino F, Brignole C, De Miglio MR, Muroni MR, Asara G, Frau M, Seddaiu MA, Calvisi DF, Feo F, Ponzoni M, Pascale RM. Chemopreventive N-(4-hydroxyphenyl) retinamide (fenretinide) targets deregulated NF-{kappa}B and Mat1A genes in the early stages of rat liver carcinogenesis. Carcinogenesis 2005; 26: 417-427
120. Calvisi DF, Ladu S, Hironaka K, Factor VM, Thorgeirsson SS. Vitamin E down-modulates iNOS and NADPH oxidase in c-Myc/TGF-alpha transgenic mouse model of liver cancer. J Hepatol 2004; 41: 815-822
121. Sun MH, Han XC, Jia MK, Jiang WD, Wang M, Zhang H, Han G, Jiang Y. Expressions of inducible nitric oxide synthase and matrix metalloproteinase-9 and their effects on angiogenesis and progression of hepatocellular carcinoma. World J Gastroenterol 2005; 11: 5931-5937
122. Ikeguchi M, Ueta T, Yamane Y, Hirooka Y, Kaibara N. Inducible nitric oxide synthase and survivin messenger RNA expression in hepatocellular carcinoma. Clin Cancer Res 2002; 8: 3131-3136
123. Moriyama A, Masumoto A, Nanri H, Tabaru A, Unoki H, Imoto I, Ikeda M, Otsuki M. High plasma concentrations of nitrite/nitrate in patients with hepatocellular carcinoma. Am J Gastroenterol 1997; 92: 1520-1523
124. Calvisi DF, Pinna F, Ladu S, Pellegrino R, Muroni MR, Simile MM, Frau M, Tomasi ML, De Miglio MR, Seddaiu MA, Daino L, Sanna V, Feo F, Pascale RM. Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease. Carcinogenesis 2008; 29: 1639-1647
125. Misko TP, Moore WM, Kasten TP, Nickols GA, Corbett JA, Tilton RG, McDaniel ML, Williamson JR, Currie MG. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 1993; 233: 119-125
126. Greten FR, Karin M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett 2004; 206: 193-199
127. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998; 273: 18623-18632
128. Briassouli P, Chan F, Savage K, Reis-Filho JS, Linardopoulos S. Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha. Cancer Res 2007; 67: 1689-1695
129. Li LG, Xu HM. Inducible nitric oxide synthase, nitrotyrosine and apoptosis in gastric adenocarcinomas and their correlation with a poor survival. World J Gastroenterol 2005; 11: 2539-2544
130. Zhang J, Peng B, Chen X. Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. Clin Cancer Res 2005; 11: 7334-7343
131. Hoki Y, Hiraku Y, Ma N, Murata M, Matsumine A, Nagahama M, Shintani K, Uchida A, Kawanishi S. iNOS-dependent DNA damage in patients with malignant fibrous histiocytoma in relation to prognosis. Cancer Sci 2007; 98: 163-168
132. Cianchi F, Cortesini C, Fantappie O, Messerini L, Sardi I, Lasagna N, Perna F, Fabbroni V, Di Felice A, Perigli G, Mazzanti R, Masini E. Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer. Clin Cancer Res 2004; 10: 2694-2704
133. Rahman MA, Dhar DK, Yamaguchi E, Maruyama S, Sato T, Hayashi H, Ono T, Yamanoi A, Kohno H, Nagasue N. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res 2001; 7: 1325-1332
134. Kong G, Kim EK, Kim WS, Lee KT, Lee YW, Lee JK, Paik SW, Rhee JC. Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer. J Gastroenterol Hepatol 2002; 17: 914-921
135. Ozel E, Pestereli HE, Simsek T, Erdogan G, Karaveli FS. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in ovarian surface epithelial carcinomas: is there any correlation with angiogenesis or clinicopathologic parameters? Int J Gynecol Cancer 2006; 16: 549-555
136. Denda A, Kitayama W, Kishida H, Murata N, Tamura K, Kusuoka O, Tsutsumi M, Nishikawa F, Kita E, Nakae D, Konishi Y, Kuniyasu H. Expression of inducible nitric oxide (NO) synthase but not prevention by its gene ablation of hepatocarcinogenesis with fibrosis caused by a choline-deficient, L-amino acid-defined diet in rats and mice. Nitric Oxide 2007; 16: 164-176
137. Ghoshal AK. New insight into the biochemical pathology of liver in choline deficiency. Crit Rev Biochem Mol Biol 1995; 30: 263-273
138. Du Q, Park KS, Guo Z, He P, Nagashima M, Shao L, Sahai R, Geller DA, Hussain SP. Regulation of human nitric oxide synthase 2 expression by Wnt beta-catenin signaling. Cancer Res 2006; 66: 7024-7031
139. Calvisi DF, Factor VM, Ladu S, Conner EA, Thorgeirsson SS. Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice. Gastroenterology 2004; 126: 1374-1386
140. Epstein RJ, Leung TW. Reversing hepatocellular carcinoma progression by using networked biological therapies. Clin Cancer Res 2007; 13: 11-17
141. Gariboldi M, Pascale R, Manenti G, De Miglio MR, Calvisi D, Carru A, Dragani TA, Feo F. Analysis of loss of heterozygosity in neoplastic nodules induced by diethylnitrosamine in the resistant BFF1 rat strain. Carcinogenesis 1999; 20: 1363-1368
142. Teeguarden JG, Newton MA, Dragan YP, Pitot HC. Genome-wide loss of heterozygosity analysis of chemically induced rat hepatocellular carcinomas reveals elevated frequency of allelic imbalances on chromosomes 1, 6, 8, 11, 15, 17, and 20. Mol Carcinog 2000; 28: 51-61
143. Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene 2006; 25: 3866-3884
144. Calvisi DF, Pascale RM, Feo F. Dissection of signal transduction pathways as a tool for the development of targeted therapies of hepatocellular carcinoma. Rev Recent Clin Trials 2007; 2: 217-236